Q1 earnings were front-loaded; the key question is whether plan progress proves repeatable in the first half

In Q1 from April to June 2026, revenue was ¥49,066 million, operating profit was ¥12,311 million, profit before tax was ¥12,959 million and profit for the quarter attributable to owners of the parent was ¥10,109 million. These figures increased 24.1%, 22.1%, 23.4% and 22.5%, respectively, from the same period a year earlier, with the top line and each level of profit growing at the same time.

The full-year forecasts are revenue of ¥200,000 million, operating profit of ¥38,000 million and profit for the year attributable to owners of the parent of ¥30,300 million. Q1 progress was 24.5% for revenue, 32.4% for operating profit and 33.4% for net profit. Operating profit progress was 7.9 percentage points ahead of revenue, so it is necessary to determine whether higher-margin businesses or products led in Q1, or whether expenses are weighted toward the second half.

The Q1 operating margin was 25.1%, above the 19.0% operating margin implied by the full-year forecast. However, the timing of royalty revenue and revenue recognition for major pharmaceutical products, as well as the first-half/second-half allocation of R&D and selling expenses, has not been disclosed, so the full-year forecast cannot be judged conservative based on this gap alone. Next time, the focus will be whether the first-half operating margin can remain in the 20% range and whether the Q1 margin outperformance is temporary.

The latest earnings forecast was unchanged in the Q1 results, and the full-year dividend forecast was also maintained at ¥124 per share. However, no numerical targets for shareholder returns, such as the payout ratio or DOE, could be confirmed. Even if first-half results exceed the mechanical 50% benchmark, if the company leaves its full-year forecast unchanged, it will be important whether it can explain the assumptions for higher expenses and product development investment expected in the second half.